Clinical Trials Logo
  1. Home
  2. Hemophilia A
  3. NCT00874926
  4. Details
NCT00874926 Clinical Trial

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A Clinical Trial

Official title:
Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00874926
Other study ID # 13405
Secondary ID KG0702
Status Completed
Phase N/A
First received April 2, 2009
Last updated January 28, 2014
Start date June 2008
Est. completion date April 2013

Study information
Verified date January 2014
Source Bayer
Contact n/a
Is FDA regulated No
Health authority Bosnia: Federal Ministry of HealthGermany: Federal Institute for Drugs and Medical DevicesKazakhstan: Ethical CommissionMorocco: Ministry of Public HealthCroatia: Ethics CommitteeIsrael: Ethics CommissionRussia: Ethics CommitteeSlovenia: Ethics CommitteeRomania: Ethics CommitteeUnited Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of HealthTunisia: Office of Pharmacies and MedicinesLybia: Ethics Committee
Study type Observational

Clinical Trial Summary

The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of patients with haemophilia A under daily-life treatment conditions.

Recruitment information / eligibility
Status Completed
Enrollment 405
Est. completion date April 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with diagnosis of haemophilia A, treated with KOGENATE Bayer/FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE Bayer/FS. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available.

Exclusion Criteria:

- Exclusion criteria must be read in conjunction with the local product information.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Biological:
• Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Haemophilia A patients

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

Bahrain,  Bosnia and Herzegovina,  Croatia,  Germany,  Israel,  Kazakhstan,  Kuwait,  Libyan Arab Jamahiriya,  Morocco,  Oman,  Qatar,  Romania,  Russian Federation,  Saudi Arabia,  Slovenia,  Tunisia,  United Arab Emirates, 

Outcome
Type Measure Description Time frame Safety issue
Primary Efficacy and Safety of Kogenate Bayer/FS After 12 months, after 24 months Yes
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1

External Links